BioLineRx to Report First Quarter 2016 Results on May 17, 2016

Management to hold a conference call at 10:00 a.m. EDT

May 10, 2016, 08:00 ET from BioLineRx

TEL AVIV, Israel, May 10, 2016 /PRNewswire/ --

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended March 31, 2016 on Tuesday, May 17, 2016, before the U.S. markets open.

The Company will host a conference call on Tuesday, May 17 at 10:00 a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx's website, http://www.biolinerx.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-407-2553 from the U.S. or +972-3-918-0644 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at http://www.biolinerx.com. A dial-in replay of the call will be available until May 20, 2016; please dial 1-888-295-2634 from the U.S. or +972-3-925-5945 internationally.

About BioLineRx 

BioLineRx is a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's leading therapeutic candidates are: BL-8040, a cancer therapy platform, which has successfully completed a Phase 2 study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease and gluten sensitivity, which has successfully completed a Phase 1/2 study. In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently signed a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2 study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA®.

For additional information on BioLineRx, please visit the Company's website at http://www.biolinerx.com, where you can review the Company's SEC filings, press releases, announcements and events. BioLineRx industry updates are also regularly updated on Facebook, Twitter, and LinkedIn.

Contact: 

PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com

or

Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipihai5@gmail.com


SOURCE BioLineRx